vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and KILROY REALTY CORP (KRC). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $272.2M, roughly 1.0× KILROY REALTY CORP). KILROY REALTY CORP runs the higher net margin — 6.3% vs -45.7%, a 52.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -5.0%). KILROY REALTY CORP produced more free cash flow last quarter ($450.3M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -1.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
GH vs KRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $272.2M |
| Net Profit | $-128.5M | $17.1M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | 6.3% |
| Revenue YoY | 39.4% | -5.0% |
| Net Profit YoY | -15.8% | -73.7% |
| EPS (diluted) | $-1.01 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $272.2M | ||
| Q3 25 | $265.2M | $279.7M | ||
| Q2 25 | $232.1M | $289.9M | ||
| Q1 25 | $203.5M | $270.8M | ||
| Q4 24 | $201.8M | $286.4M | ||
| Q3 24 | $191.5M | $289.9M | ||
| Q2 24 | $177.2M | $280.7M | ||
| Q1 24 | $168.5M | $278.6M |
| Q4 25 | $-128.5M | $17.1M | ||
| Q3 25 | $-92.7M | $162.3M | ||
| Q2 25 | $-99.9M | $79.6M | ||
| Q1 25 | $-95.2M | $43.7M | ||
| Q4 24 | $-111.0M | $65.0M | ||
| Q3 24 | $-107.8M | $57.7M | ||
| Q2 24 | $-102.6M | $54.5M | ||
| Q1 24 | $-115.0M | $55.7M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | — | ||
| Q3 25 | -37.3% | — | ||
| Q2 25 | -45.9% | — | ||
| Q1 25 | -54.6% | — | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | — | ||
| Q2 24 | -56.8% | — | ||
| Q1 24 | -59.2% | — |
| Q4 25 | -45.7% | 6.3% | ||
| Q3 25 | -35.0% | 58.0% | ||
| Q2 25 | -43.0% | 27.4% | ||
| Q1 25 | -46.8% | 16.1% | ||
| Q4 24 | -55.0% | 22.7% | ||
| Q3 24 | -56.3% | 19.9% | ||
| Q2 24 | -57.9% | 19.4% | ||
| Q1 24 | -68.2% | 20.0% |
| Q4 25 | $-1.01 | $0.11 | ||
| Q3 25 | $-0.74 | $1.31 | ||
| Q2 25 | $-0.80 | $0.57 | ||
| Q1 25 | $-0.77 | $0.33 | ||
| Q4 24 | $-0.90 | $0.50 | ||
| Q3 24 | $-0.88 | $0.44 | ||
| Q2 24 | $-0.84 | $0.41 | ||
| Q1 24 | $-0.94 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $179.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $5.4B |
| Total Assets | $2.0B | $10.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $179.3M | ||
| Q3 25 | $580.0M | $372.4M | ||
| Q2 25 | $629.1M | $193.1M | ||
| Q1 25 | $698.6M | $146.7M | ||
| Q4 24 | $525.5M | $165.7M | ||
| Q3 24 | $585.0M | $625.4M | ||
| Q2 24 | $933.7M | $835.9M | ||
| Q1 24 | $1.0B | $855.0M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $5.4B | ||
| Q3 25 | $-354.5M | $5.5B | ||
| Q2 25 | $-305.5M | $5.4B | ||
| Q1 25 | $-250.8M | $5.4B | ||
| Q4 24 | $-139.6M | $5.4B | ||
| Q3 24 | $-60.1M | $5.4B | ||
| Q2 24 | $-1.6M | $5.4B | ||
| Q1 24 | $68.3M | $5.4B |
| Q4 25 | $2.0B | $10.9B | ||
| Q3 25 | $1.3B | $11.0B | ||
| Q2 25 | $1.3B | $10.9B | ||
| Q1 25 | $1.3B | $10.9B | ||
| Q4 24 | $1.5B | $10.9B | ||
| Q3 24 | $1.5B | $11.4B | ||
| Q2 24 | $1.6B | $11.5B | ||
| Q1 24 | $1.7B | $11.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $566.3M |
| Free Cash FlowOCF − Capex | $-54.2M | $450.3M |
| FCF MarginFCF / Revenue | -19.3% | 165.4% |
| Capex IntensityCapex / Revenue | 9.9% | 42.6% |
| Cash ConversionOCF / Net Profit | — | 33.10× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $833.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $566.3M | ||
| Q3 25 | $-35.4M | $176.6M | ||
| Q2 25 | $-60.3M | $143.7M | ||
| Q1 25 | $-62.7M | $136.9M | ||
| Q4 24 | $-64.5M | $541.1M | ||
| Q3 24 | $-51.1M | $176.3M | ||
| Q2 24 | $-94.0M | $88.7M | ||
| Q1 24 | $-30.3M | $167.9M |
| Q4 25 | $-54.2M | $450.3M | ||
| Q3 25 | $-45.8M | $148.7M | ||
| Q2 25 | $-65.9M | $118.4M | ||
| Q1 25 | $-67.1M | $115.6M | ||
| Q4 24 | $-83.4M | $440.8M | ||
| Q3 24 | $-55.3M | $147.2M | ||
| Q2 24 | $-99.1M | $69.5M | ||
| Q1 24 | $-37.2M | $151.9M |
| Q4 25 | -19.3% | 165.4% | ||
| Q3 25 | -17.3% | 53.1% | ||
| Q2 25 | -28.4% | 40.9% | ||
| Q1 25 | -33.0% | 42.7% | ||
| Q4 24 | -41.3% | 153.9% | ||
| Q3 24 | -28.9% | 50.8% | ||
| Q2 24 | -55.9% | 24.7% | ||
| Q1 24 | -22.1% | 54.5% |
| Q4 25 | 9.9% | 42.6% | ||
| Q3 25 | 3.9% | 10.0% | ||
| Q2 25 | 2.4% | 8.7% | ||
| Q1 25 | 2.2% | 7.9% | ||
| Q4 24 | 9.4% | 35.0% | ||
| Q3 24 | 2.2% | 10.1% | ||
| Q2 24 | 2.9% | 6.8% | ||
| Q1 24 | 4.1% | 5.7% |
| Q4 25 | — | 33.10× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 8.32× | ||
| Q3 24 | — | 3.06× | ||
| Q2 24 | — | 1.63× | ||
| Q1 24 | — | 3.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
KRC
Segment breakdown not available.
